PatternsRadar
Sign in

COHANCECohance Lifesciences Limited

NSE
Full chart
457.00INR+10.20 (+2.28%)Close · 6 Oct 2026
5 Aug 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹17,485 CrMarket cap
166.6P/E (TTM)
46.3%Delivery

Filings & corporate actions

25 results filed
CSV
Next results · Q2 FY27
Expected 6 Nov 2026 – 13 Nov 2026
Estimate: filed 37–44 days after quarter end, last 5 times
Dividend
₹6.00 per share · last 9 Sept 2022
2026
  • 5 AugresultsResults · Q1 FY27 · consolidated and standalone+2.2%NSE
  • 17 JulshareholdingShareholding · 30 Jun 20260.0%NSE
  • 12 MayresultsResults · Q4 FY26 · consolidated and standalone-5.8%NSE
  • 21 AprshareholdingShareholding · 31 Mar 2026-2.2%NSE
  • 12 FebresultsResults · Q3 FY26 · consolidated and standalone-10.0%NSE
  • 21 JanshareholdingShareholding · 31 Dec 2025-4.0%NSE

Reaction to results · all yearsrose on day 0 in 10 of 25 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY275 Aug 2026+2.2%+3.4%+7.3%11.0×
Q4 FY2612 May 2026-5.8%-13.3%-12.6%0.7×
Q3 FY2612 Feb 2026-10.0%-12.9%-16.3%7.3×
Q2 FY2612 Nov 2025-8.8%-15.7%-23.1%6.9×
Q1 FY2613 Aug 2025-7.3%-10.3%-0.1%5.7×
Q4 FY2528 May 2025-3.8%-4.1%-9.6%1.4×
Q3 FY2513 Feb 2025-2.7%+9.5%+1.2%0.9×
Q2 FY2513 Nov 2024+1.0%+2.5%+0.5%1.1×
Q1 FY259 Aug 2024+4.7%+0.2%+22.8%1.4×
Q3 FY246 Feb 2024+1.2%+6.7%+7.3%2.0×
Q2 FY2410 Nov 2023+1.2%+2.2%+19.8%0.2×
Q1 FY248 Aug 2023+0.6%+6.4%+5.2%2.1×
Q4 FY2326 May 2023+0.3%+0.5%+2.4%0.7×
Q3 FY237 Feb 2023-0.2%-1.3%-2.4%2.1×
Q2 FY239 Nov 2022+0.4%+5.2%+4.3%6.1×
Q1 FY239 Aug 2022-8.6%-5.9%-0.6%2.7×
Q4 FY2210 May 2022-6.0%-7.8%-13.5%1.7×
Q3 FY229 Feb 2022-5.1%-3.8%-10.6%0.8×
Q2 FY226 Nov 2021-1.1%+1.7%-0.3%2.4×
Q1 FY2213 Aug 2021+3.1%+0.2%-0.7%0.7×
Q4 FY219 Jun 2021-5.1%-2.5%-4.9%4.3×
Q3 FY2111 Feb 2021-3.1%-2.0%-6.4%2.5×
Q2 FY2131 Oct 2020-4.4%+5.1%+20.9%2.1×
Q1 FY2118 Aug 2020-5.9%+1.2%+10.3%2.6×
Q4 FY2019 Jun 2020+16.3%+41.7%+70.9%8.1×
Average-1.9%+0.3%+2.9%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY-23.1%
Profit YoY-197.4%
Interest cost YoY+110.1%
Revenue QoQ-31.8%
Profit QoQ-643.8%
CAGR2Y3Y4Y5Y6Y7Y
Revenue—+25.9%+17.8%+21.0%——
Profit—-37.2%-30.7%-22.5%——

Key data

CSV
Open448.30
Day range445.50 – 459.20
52-week range266.70 – 917.85
From 52w high-50.2%
RSI (14)53.5
ATR (14)17.15
Volume4.93L
Avg volume (20D)12.50L
Rel volume0.39×
Volatility (1Y)49.2%
Turnover₹22.5Cr
SMA 50 / 200446.80 / 415.56

Delivery percentage

Latest · 6 Oct 202646.3%
20-day avg48.5%
1-year avg45.2%
Percentile (own history)25th
Range5.5–100.0%
Sessions1,624

Over the last 20 sessions COHANCE settled 48.5% of its traded quantity, which is above average for an NSE equity. Its one-year average is 45.2%, so recent sessions are running 3.3 points higher than usual. The latest session ranks higher than 25% of the 1,624 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price+2.28%+0.82%-0.84%+3.31%+48.74%-47.43%

Valuation

CSV
Market cap₹17,485 Cr
P/E (TTM)166.6
EPS (TTM)2.74
Shares outstanding38.26Cr
Listed9 Mar 2020

Ownership

CSV
Promoter57.49%
Promoter Δ QoQ0.00 pp
Public42.51%
FII6.50%
DII20.09%
Pledged94.56%

Quarterly results · consolidated

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)555.6544.6619.1422.3
YoY chg+115.6%+77.3%+54.0%-23.1%
Net profit (₹ Cr)66.429.08.3(45.2)
YoY chg-19.0%-65.2%-78.5%-197.4%
Net margin11.9%5.3%1.3%-10.7%
EPS1.930.960.50-0.65

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 57.49% · public 42.51%
30 Sept 2021: promoter 60.00%31 Dec 2021: promoter 60.00%31 Mar 2022: promoter 60.00%30 Jun 2022: promoter 60.00%30 Sept 2022: promoter 60.00%31 Dec 2022: promoter 60.00%31 Mar 2023: promoter 60.01%30 Jun 2023: promoter 60.00%30 Sept 2023: promoter 60.00%31 Dec 2023: promoter 60.00%31 Mar 2024: promoter 50.10%30 Jun 2024: promoter 50.10%30 Sept 2024: promoter 50.10%31 Dec 2024: promoter 50.10%31 Mar 2025: promoter 50.10%9 May 2025: promoter 66.41%30 Jun 2025: promoter 66.41%30 Sept 2025: promoter 57.49%31 Dec 2025: promoter 57.49%31 Mar 2026: promoter 57.49%30 Jun 2026: promoter 57.49%
2021-092026-06
  • Promoter
  • Public and others
Promoter
57.49%
Public
42.51%
Promoter change
0.00 pp
Filed
17 Jul 2026
FII
6.50%
DII
20.09%
Promoter pledged
94.56%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
₹ crore, as filed
 Q1 FY24Q2 FY24Q3 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26RQ3 FY26Q4 FY26Q1 FY27
Revenue from operations347.6231.1219.8230.7257.7307.2402.0549.3555.6544.6619.1422.3
Other income10.719.814.318.214.115.710.614.215.66.2(1.8)12.3
Total income358.2250.9234.2248.8271.8322.9412.6563.5571.2550.7617.3434.5
Total expenses194.3145.5168.7165.8172.3213.1361.0492.6487.4505.3580.9477.4
└ Finance costs1.10.51.31.61.73.35.810.28.89.19.26.7
└ Depreciation12.511.912.813.417.020.426.845.144.046.951.249.5
Profit before tax163.9105.465.583.199.5109.751.662.883.840.619.9(42.9)
Tax expense43.425.818.722.317.526.412.916.417.411.611.62.3
Net profit120.679.646.860.882.083.338.746.466.429.08.3(45.2)
EPS4.743.131.842.393.233.261.651.281.940.960.51-0.63
Net margin34.70%34.44%21.27%26.34%31.81%27.12%9.63%8.45%11.95%5.33%1.34%-10.70%
PBT margin47.17%45.62%29.78%36.01%38.61%35.73%12.84%11.43%15.08%7.46%3.22%-10.15%
Tax rate26.44%24.52%28.59%26.87%17.61%24.10%24.94%26.07%20.75%28.52%58.26%—

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 5 Aug 2026.

COHANCE at a glance

  • COHANCE closed at ₹457 on 6 Oct 2026, +2.28% on the day, -47.4% over one year, 50.2% below its 52-week high of ₹917.85.
  • Delivery was 46.3% of traded quantity on 6 Oct 2026, the 25th percentile of its own 1,624 sessions with a reading (20-session average 48.5%, 1-year average 45.2%).
  • Market capitalisation is ₹17,485 crore at a trailing P/E of 166.6 (trailing EPS ₹2.74).
  • Q1 FY27 results (consolidated, filed 5 Aug 2026): revenue ₹422 crore (-23.1% year on year), net profit ₹-45 crore (-197.4%); the price moved +2.2% on the first session after.
  • Promoters held 57.49% at 30 Jun 2026, unchanged on the previous filing, with 94.56% of promoter shares pledged.
  • Q2 FY27 results are expected between 6 Nov 2026 and 13 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE03QK01018
SeriesEQ
Listed9 Mar 2020
History from9 Mar 2020
Sessions1,630
Turnover rank#446

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE